BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has earned a consensus recommendation of “Moderate Buy” from the fourteen analysts that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and ten have given a buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $19.3333.

Several equities research analysts have recently commented on the company. JMP Securities increased their price objective on BioCryst Pharmaceuticals from $17.00 to $27.00 and gave the company a “market outperform” rating in a report on Wednesday, October 15th. Cantor Fitzgerald upped their price target on shares of BioCryst Pharmaceuticals from $24.00 to $26.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 15th. Evercore ISI reissued an “in-line” rating and issued a $8.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Wednesday, October 1st. Wall Street Zen upgraded shares of BioCryst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 26th. Finally, Needham & Company LLC dropped their target price on shares of BioCryst Pharmaceuticals from $20.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday, November 4th.

BioCryst Pharmaceuticals Price Performance

Shares of NASDAQ BCRX opened at $7.00 on Wednesday. The stock has a market capitalization of $1.47 billion, a price-to-earnings ratio of -38.89 and a beta of 1.09. The business has a 50-day moving average of $7.29 and a 200-day moving average of $8.60. BioCryst Pharmaceuticals has a fifty-two week low of $6.00 and a fifty-two week high of $11.31.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings results on Monday, November 3rd. The biotechnology company reported $0.06 EPS for the quarter, missing the consensus estimate of $0.07 by ($0.01). The company had revenue of $159.40 million during the quarter, compared to analysts’ expectations of $162.91 million. The business’s revenue was up 36.1% on a year-over-year basis. During the same period in the previous year, the business earned ($0.07) earnings per share. BioCryst Pharmaceuticals has set its FY 2025 guidance at EPS. On average, sell-side analysts expect that BioCryst Pharmaceuticals will post -0.36 EPS for the current year.

Institutional Trading of BioCryst Pharmaceuticals

A number of hedge funds have recently made changes to their positions in BCRX. Headlands Technologies LLC acquired a new position in shares of BioCryst Pharmaceuticals during the 1st quarter worth approximately $32,000. New Age Alpha Advisors LLC bought a new position in BioCryst Pharmaceuticals during the first quarter worth $62,000. Family Legacy Financial Solutions LLC bought a new position in BioCryst Pharmaceuticals during the second quarter worth $72,000. Focus Partners Wealth acquired a new position in shares of BioCryst Pharmaceuticals in the third quarter valued at $77,000. Finally, Farther Finance Advisors LLC raised its position in shares of BioCryst Pharmaceuticals by 326.8% in the third quarter. Farther Finance Advisors LLC now owns 10,590 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 8,109 shares during the period. 85.88% of the stock is owned by institutional investors and hedge funds.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.